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Summary
Background In 1975–99, only 1·1% of new therapeutic products had been developed for neglected diseases. Since 
then, several public and private initiatives have attempted to mitigate this imbalance. We analysed the research and 
development pipeline of drugs and vaccines for neglected diseases from 2000 to 2011.
Methods We searched databases of drug regulatory authorities, WHO, and clinical trial registries for entries made 
between Jan 1, 2000, and Dec 31, 2011. We deﬁ ned neglected diseases as malaria, tuberculosis, diarrhoeal diseases, 
neglected tropical diseases (NTDs; WHO deﬁ nition), and other diseases of poverty according to common deﬁ nitions.
Findings Of the 850 new therapeutic products registered in 2000–11, 37 (4%) were indicated for neglected diseases, 
comprising 25 products with a new indication or formulation and eight vaccines or biological products. Only four 
new chemical entities were approved for neglected diseases (three for malaria, one for diarrhoeal disease), accounting 
for 1% of the 336 new chemical entities approved during the study period. Of 148 445 clinical trials registered in 
Dec 31, 2011, only 2016 (1%) were for neglected diseases.
Interpretation Our ﬁ ndings show a persistent insuﬃ  ciency in drug and vaccine development for neglected diseases. 
Nevertheless, these and other data show a slight improvement during the past 12 years in new therapeutics development 
and registration. However, for many neglected diseases, new therapeutic products urgently need to be developed and 
delivered to improve control and potentially achieve elimination.
Funding None.
Introduction
Neglected diseases, understood broadly as diseases 
aﬀ ecting populations in mainly low-income countries, 
are a leading cause of mortality, chronic disability, and 
poverty.1–3 The need for greater political commitment to 
combat these diseases has been recognised by many 
World Health Assembly resolutions and the UN 
Millennium Development Goals.4,5
An analysis of drug development trends published in 
2002 showed that only 1·1% of all drugs approved over 
the preceding 25 years (1975–99) were for neglected 
diseases,6 despite these diseases accounting for 12% of 
the global health burden. The lack of appropriate research 
and development investment has been attributed to the 
absence of ﬁ nancial return for pharmaceutical and 
biotechnology companies, and a failure of public policy 
to establish suﬃ  cient enabling policies.7–9
We aimed to assess the state of research and 
development for neglected diseases over the past 12 years 
compared with other diseases.
Methods
Deﬁ nition of neglected disease
Several deﬁ nitions of neglected diseases are in common 
use. For this analysis, we used a broad deﬁ nition, 
combining all terms from the following sources: the 
WHO list of neglected tropical diseases (NTDs),10 papers 
by Trouiller and colleagues6 and Hotez and colleagues,11 
PLoS Neglected Tropical Diseases journal disease scope,12 
G-FINDER 2011 report,13 and the BIO Ventures for Global 
Health 2012 report.14
We included all diseases mentioned at least once in 
these sources, with the exception of several infections 
not uniquely endemic in low-income countries, including 
HIV/AIDS, meningitis, bacterial pneumonia, and 
rheumatic fever. We identiﬁ ed 49 neglected diseases, 
separating them into ﬁ ve categories: malaria, 
tuberculosis, diarrhoeal diseases, NTDs (WHO list of 
17 NTDs),10 or other neglected diseases (list of 19 not 
ﬁ tting into the other categories). The complete list of 
diseases is given in the appendix.
Approved products analysis
We identiﬁ ed newly approved drug and vaccine products 
by searching the European Medicines Agency15 and the 
US Food and Drug Administration (FDA) databases.16 We 
included all products approved across all indications 
from Jan 1, 2000, to Dec 31, 2011. For neglected diseases, 
we also searched regulatory databases of the following 
countries, which are all signatories of the Pharmaceutical 
Inspection Convention and Pharmaceutical Inspection 
Co-operation Scheme:17 European Union member states 
(Belgium, Czech Republic, Denmark, Estonia, France, 
Germany, Greece, Hungary, Portugal, Spain, Sweden, 
The Netherlands, and the UK), Canada, Australia, 
Switzerland, Iceland, and Argentina, and the regulatory 
databases of Japan, India, and Brazil. We used the earliest 
date of product approval listed in any of the above 
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databases. We also searched for new products included 
on the WHO List of Prequaliﬁ ed Medicinal Products18 
and the WHO Model List of Essential Medicines 
(Essential Medicines List).19
We classiﬁ ed new products into one of the following 
types: new chemical entity (NCE), new indication, new 
formulation, new ﬁ xed-dose combination, and vaccine or 
biological product. We also compared disease indications 
of all product approvals with global disease burden 
through analysis of 2004 WHO disability-adjusted life-
years (DALYs).1
For each registered product, we identiﬁ ed the 
marketing authorisation holder for the application and 
for the ﬁ rst submission in the regulatory database. For 
prequaliﬁ ed products, this information was available in 
the WHO database. This information was not available 
for products on the WHO Essential Medicines List 
because the international non-proprietary name, and not 
the marketed name, of the product is used. For these 
cases, we used the name of the dossier applicant for the 
product. We assessed the medical beneﬁ t (or innovation) 
of a given product using inclusion on the WHO Essential 
Medicines List as a proxy measure.
Clinical trials analysis
We assessed the clinical development pipeline for 
neglected-disease therapeutics by examining the number 
of ongoing phase 1–3 clinical trials listed in the US 
National Institutes of Health (NIH) clinical trials 
database,20 and the WHO registry of clinical trials,21 
between Sept 1, 1999 (when the database was launched), 
and Dec 31, 2011. We also recorded all trials that were 
ongoing during the month of December, 2011. In the NIH 
database analysis, we included interventional and open 
phase 1–3 clinical trials. We excluded phase 4 studies; 
trials categorised as closed, withdrawn, terminated, 
suspended, or completed; and trials in which the main 
indication was misclassiﬁ ed in the registry database. 
Additionally, for neglected diseases, we included studies 
classiﬁ ed as closed (not recruiting or enrolling by 
invitation only) but still active; we included interventional 
studies with no deﬁ ned clinical-trial phase on a case-by-
case basis (78 studies included). In the WHO registry, we 
included interventional and currently recruiting studies. 
Studies already listed in the NIH database, phase 4 
studies, and trials in which the main indication was 
misclassiﬁ ed were excluded. Recruitment status was 
unknown for 23 interventional studies, and these studies 
were not included in the analysis.
For each clinical trial, product type was classiﬁ ed as for 
approved products (NCE, new indication, new 
formulation, ﬁ xed-dose combination, or vaccine or 
biological product). Additionally, when approved drugs 
were combined for a neglected-disease indication but not 
manufactured as a ﬁ xed-dose combination, we classiﬁ ed 
them as a new association of registered drugs.
We classiﬁ ed clinical trial sponsors into four categories: 
public organisations (including government, academic, 
and public research institutes); private not-for-proﬁ t 
organisations (including product development 
partnerships, charities, foundations, and philanthropic 
institutions); private industry, for-proﬁ t entities (including 
pharmaceutical and biotechnology companies); and a 
mixed-sponsor category when products were studied in 
clinical trials by diﬀ erent categories of sponsors.
Finally, for each neglected disease, we assessed the 
existence of a vaccine or other intervention to prevent 
the infection. After assessing new products in 
NCE 
(n=336)
Other new product 
(n=420)*





Malaria 3 (1%) 9 (2%) 0 12 (1%)
Tuberculosis 0 7 (2%) 0 7 (1%)
Diarrhoeal diseases 1 (<0·5%) 3 (1%) 3 (3%) 7 (1%)‡
Neglected tropical diseases 0 5 (1%) 0 5 (1%)§
Other 0 1 (<0·5%) 5 (5%) 6 (1%)¶
Subtotal 4 (1%) 25 (6%) 8 (9%) 37 (4%)
Other infectious diseases 35 (10%) 48 (11%) 66 (70%) 149 (18%)
All other diseases 297 (88%) 347 (83%) 20 (21%) 664 (78%)
Data are n (%). NCE=new chemical entity. *New indication, new formulation, or ﬁ xed-dose combination. †Includes 
immunoglobulins and other biological products. ‡For diarrhoea, cholera, cryptosporidiosis, and giardiasis. §For 
human African trypanosomiasis, Chagas disease, and leishmaniasis. ¶For Japanese encephalitis, haemorrhagic fevers, 
and snakebite.
Table 1: New therapeutic products approved or recommended, by disease category (2000–11)
All new products* NCEs only DALYs (in thousands)
Neuropsychiatric disorders 134 (16%) 49 (15%) 199 280 (13%)
Cancer 103 (12%) 81 (24%) 79 765 (5%)
Cardiovascular diseases 70 (8%) 29 (9%) 151 377 (10%)
Genitourinary system and sex hormones 55 (7%) 18 (5%) 14 754 (1%)
Digestive diseases 46 (5%) 23 (7%) 42 498 (3%)
Sense organ disorders 37 (4%) 13 (4%) 86 883 (6%)
Neglected diseases 37 (4%) 4 (1%) 159 976 (11%)
Malaria 12 (1%) 3 (1%) 33 976 (2%)
Tuberculosis 7 (1%) 0 34 217 (2%)
Diarrhoeal diseases 7 (1%) 1 (<0·5%) 72 777 (5%)
Neglected tropical diseases 5 (1%) 0 18 325 (1%)
Other neglected diseases 6 (1%) 0 681 (<0·5%)
HIV/AIDS 36 (4%) 12 (4%) 58 513 (4%)
Respiratory diseases (non-infectious) 31 (4%) 7 (2%) 59 039 (4%)
Diabetes mellitus 28 (3%) 9 (3%) 19 705 (1%)
Musculoskeletal diseases 26 (3%) 13 (4%) 30 869 (2%)
Other infectious and parasitic diseases 113 (13%) 23 (7%) 181 441 (12%)
All other diseases† 134 (16%) 55 (16%) 439 159 (29%)
Total 850 (100%) 336 (100%) 1 523 259 (100%)
Data are n (%). *Includes NCEs, new formulations, ﬁ xed-dose combinations, new indications, and vaccines or 
biologicals. †Maternal and perinatal disorders, nutritional deﬁ ciencies, congenital abnormalities, skin diseases, 
endocrine disorders, oral diseases, and injuries.
Table 2: Disease indications of all new products and of new chemical entities (NCEs) compared with 
worldwide disability-adjusted life-years (2004 DALYs; 2000–11)
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Formulation Product type Year of 
approval
Authority Marketing authorisation holder
Malaria
Artemotil Injectable NCE 2000 MEB (Netherlands) Artecef BV
Atovaquone plus proguanil (paediatric) Tablet NI 2000 FDA (USA) GlaxoSmithKline
Proguanil plus chloroquine Tablet FDC 2001 AFSSAPS (France) AstraZeneca
Chloroquine plus primaquine Tablet FDC 2001 ANVISA (Brazil) Industria química do Estado de Goiás S/A- Iquedo, 
Brazil
Artesunate* Injectable NF 2001 ANVISA (Brazil) Silvestre Labs Química e Farmacêutica Ltda, Brazil
Artemether plus lumefantrine* Dispersible tablet NF 2008 Swissmedic 
(Switzerland)
Novartis Pharma Schweiz AG
Artesunate plus amodiaquine (ASAQ)* Tablet FDC 2008 WHO PQ Sanoﬁ -Aventis Group
Artesunate plus meﬂ oquine (ASMQ) Tablet FDC 2008 ANVISA (Brazil) Farmanguinhos/Fiocruz, Brazil
Artemether plus lumefantrine Oral suspension NF 2008 CDSCO (India) Information not available 
Arterolane maleate plus piperaquine phosphate Tablet NCE 2011 CDSCO (India) Ranbaxy Labs
Piperaquine tetraphosphate plus alpha dihydroartemisinin Tablet NCE 2011 EMEA (Europe) Sigma-Tau Industrie Farmaceutiche Riunite SpA
Artesunate* Rectal suppository NF 2000 ANVISA (Brazil) Nova Química Farmacêutica Ltda, Brazil
Tuberculosis
Ethambutol plus isoniazid plus pyrazinamide plus 
rifampicin*
Tablet FDC 2003 WHO PQ Lupin Ltd, India
Ethambutol plus isoniazid plus rifampicin* Tablet FDC 2008 WHO PQ Macleods Pharmaceuticals Ltd, India
Isoniazid plus rifampicin Dispersible tablet NF 2009 WHO PQ Macleods Pharmaceuticals Ltd, India
Isoniazid plus pyrazinamide plus rifampicin Dispersible tablet NF 2009 WHO PQ Macleods Pharmaceuticals Ltd, India
Moxiﬂ oxacin* Tablet NI 2010 WHO PQ Cipla Ltd, India
Levoﬂ oxacin* Tablet NI 2011 WHO PQ Cipla Ltd, India
Oﬂ oxacin* Tablet NI 2011 WHO PQ Cipla Ltd, India
Chagas disease
Benznidazole (paediatric) Dispersible tablet NF 2011 ANVISA (Brazil)  LAFEPE, Brazil
Visceral leishmaniasis
Miltefosine* Capsule NI 2002 CDSCO (India) German Remedies Ltd, Mumbai
Paromomycin* Injectable NI 2006 CDSCO (India) Gland Pharma United and OneWorld Health 
(San Francisco, [IOWH]) and the Bill & Melinda Gates 
Foundation
Cutaneous leishmaniasis
Miltefosine Capsule NI 2008 CDSCO (India) German Remedies Ltd, Mumbai
Cryptosporidosis/giardiasis
Nitazoxanide Oral suspension NF 2002 FDA (USA) Romark Laboratories, LC
Nitazoxanide Tablet NCE 2004 FDA (USA) Romark Laboratories, LC
Cholera
Tosuﬂ oxacin tosilate hydrate Granules NF 2009 PMDA (Japan) Toyama Chemical Co, Ltd
Bivalent inactivated vaccine, killed whole cells of Vibrio 
cholerae O1 and O139
Oral suspension Vaccine 2009 CDSCO (India) Shantha Biotech
Rotavirus
Live pentavalent vaccine, for prevention of G1, G2, G3, G4, 
and G-serotypes containing P1A[8], in Vero cells
 Oral suspension Vaccine 2006 EMEA (Europe) Sanoﬁ  Pasteur MSD, SNC
Live, attenuated vaccine, rotavirus RIX4414 strain, for 
prevention of G1 and non-G1 serotypes (G3, G4, and G9), 
in Vero cells
Oral suspension Vaccine 2006 EMEA (Europe) GlaxoSmithKline Biologicals SA
Japanese encephalitis
Japanese encephalitis virus vaccine, freeze-dried, 
inactivated, Beijing-1 strain, Vero cell-derived
Injectable Vaccine 2006 PMDA (Japan) Kaketsuken
Japanese encephalitis virus vaccine, live chimeric viral 
vector
Injectable Vaccine 2008 TGA (Australia) Sanoﬁ  Pasteur Pty Ltd
Japanese encephalitis virus vaccine, puriﬁ ed, formalin-
inactivated, whole virus vaccine strain SA14-14-2, 
in Vero cells
Injectable Vaccine 2009 EMEA (Europe) Intercell AG
(Continues on next page)
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development in 2011, we classiﬁ ed the neglected diseases 
into three categories of research and development need: 
diseases with no crucial clinical gaps in research and 
development (those for which either preventive 
measures or at least two ﬁ eld-adapted, safe, eﬀ ective 
treatments to respond to drug resistance exist); diseases 
with crucial gaps in research and development and with 
ongoing clinical research; and diseases with crucial gaps 
in research and development but with no ongoing 
clinical research.
Role of the funding source
There was no funding source for this study. The 
corresponding author had full access to all the data in the 
study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
850 new therapeutic products (NCEs, new indications, 
new formulations, ﬁ xed-dose combinations, and vaccines 
and biologicals) were approved by diﬀ erent regulatory 
bodies between Jan 1, 2000, and Dec 31, 2011. Of these, 
37 (4%) were for neglected diseases, including 29 drugs 
and eight vaccines (table 1). Collectively, neglected diseases 
accounted for about a tenth of the global disease burden 
in 2004 (table 2).
Of the 336 NCEs approved between 2000 and 2011, only 
four (1%) were for neglected diseases. Among the other 
product types, 25 (6%) of 420 new indications, new 
formulations, and ﬁ xed-dose combinations, and eight (9%) 
of 94 vaccines and biologicals, were for neglected diseases. 
Of these 37 new products approved for neglected diseases, 
most were for malaria (n=12), including three of the four 
NCEs (table 3). The other NCE was indicated for diarrhoeal 
disease (cryptosporidiosis or giardiasis). No NCE was 
developed in 2000–11 for tuberculosis or any NTDs. The 
vaccines and biologicals approved were for Japanese 
encephalitis (n=4) and diarrhoeal diseases (n=3), with one 
antivenom developed for snakebite.
23 (7%) NCEs were approved for other infectious and 
parasitic diseases, which accounted for about 12% of total 
disease burden (table 2). By contrast with those for 
infectious diseases, 24% of all NCEs were indicated for 
cancer, which accounted for about 5% of the global 
disease burden. The next largest categories of NCE 
approvals were for neuropsychiatric disorders and 
cardiovascular diseases (table 2).
In terms of medical beneﬁ t, 14 (48%) of the 29 new 
products (excluding vaccines and biologicals) approved 
for neglected diseases in 2000–11 were included in the 
WHO Essential Medicines List, by contrast with only 
Formulation Product type Year of 
approval
Authority Marketing authorisation holder
(Continued from previous page)
Japanese encephalitis virus vaccine, live, attenuated strain 
SA14-14-2, in primary hamster kidney cell cultures
Injectable Vaccine 2010 CDSCO (India) Curevin Pharma Pvt
Snakebite
Crotalidae polyvalent immune fab (ovine) Injectable Biologic 
(anti-venom)
2000 FDA (USA) Protherics Inc.
Human African trypanosomiasis
Nifurtimox (combination therapy with eﬂ ornithine)* Tablet NI 2009 WHO EML Drugs for Neglected Diseases initiative (DNDi)
Diarrhoea
Zinc* Tablet and liquid NI 2006 WHO EML Newborn and Child Development Department of 
Child and Adolescent Health, WHO
Viral haemorrhagic fevers†
Ribavirin* Intravenous and oral NI 2007 WHO EML Biorisk Reduction for Dangerous Pathogens Team 
(BDP), WHO
Tuberculosis indications for oﬂ oxacin, levoﬂ oxacin, and moxiﬂ oxacin were not recognised by the regulatory authorities in this analysis but were recorded in the WHO List of Prequaliﬁ ed Medicinal Products and 
Essential Medicines List, for multidrug-resistant tuberculosis. EMA=European Medicines Agency. FDA=Food and Drug Administration. FDC=ﬁ xed-dose combination. NCE=new chemical entity. NF=new 
formulation. NI=new indication. WHO EML=WHO Essential Medicines List. WHO PQ=WHO List of Prequaliﬁ ed Medicinal Products. *Included in WHO Essential Medicines List 2011, excluding biologicals. †Lassa 
fever, Argentine haemorrhagic fever (AHF), Crimean-Congo haemorrhagic fever, and haemorrhagic fever with renal syndrome.
Table 3: New therapeutic products approved or recommended for neglected diseases, 2000–11
NIH WHO Total
Neglected diseases
Malaria 508 (<0·5%) 186 (1%) 694 (1%)
Tuberculosis* 378 (<0·5%) 96 (<0·5%) 474 (<0·5%)
Diarrhoeal 
diseases†
221 (<0·5%) 49 (<0·5%) 270 (<0·5%)
NTDs‡ 319 (<0·5%) 101 (<0·5%) 420 (<0·5%)
Other§ 115 (<0·5%) 43 (<0·5%) 158 (<0·5%)
Subtotal 1541 (1%) 475 (2%) 2016 (1%)
All other diseases 117 093 (99%) 29 336 (98%) 146 429 (99%)
Total 118 634 (100%) 29 811 (100%) 148 445 (100%)
Data are n (%). NIH=National Institutes of Health. NTD=neglected tropical disease 
(WHO deﬁ nition). *Two studies on HIV, tuberculosis, and malaria were included. 
†Rotavirus (122 trials), cholera (29 trials). ‡Leishmaniasis (121 trials), dengue 
fever (79 trials), schistosomiasis (26 trials). §Japanese encephalitis (60 trials).
Table 4: Clinical trials by disease category and registry (as of Dec 31, 2011)
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26 (4%) of 727 for all other diseases. 30 (81%) of 37 new 
product registrations were ﬁ led by regional generic or 
public pharmaceutical companies, including 12 by 
Indian manufacturers. Seven product registrations were 
ﬁ led by large, private pharmaceutical companies.
Between Sept 1, 1999, and Dec 31, 2011, 148 445 clinical 
trials for all diseases were registered in the NIH and 
WHO databases, only 2016 (1%) of which were for 
neglected diseases (table 4). As of Dec 31, 2011, we 
identiﬁ ed 383 active clinical trials for neglected 
diseases—malaria and tuberculosis accounted for more 
than half these trials (table 5).
Of the 383 active clinical trials for neglected diseases, 
122 (32%) are testing a new vaccine candidate or 
biological product; 57 (15%) are testing a new formulation 
(including ﬁ xed-dose combinations), indication, or 
association; and 24 (6%) are testing an NCE. The 
remainder (180 studies) are directed at follow-up studies 
or testing new dosages or alternative regimens (n=43); an 
approved drug for geographical extension (n=32); dietary 
supplements and adjunct therapies (n=23); drugs to treat 
disease complications (n=16); studies of subpopulations 
with HIV (n=16); prevention interventions (n=12); 
studies in pregnancy (n=11); diagnostics (n=8), or other 
procedures (n=8); challenge studies (n=7); or 
pharmacological studies (n=4).
123 new products are being tested in these 383 active 
clinical trials for neglected diseases (table 6). Most 
products in development are vaccines and biological 
products (table 6). Slightly more than a quarter of products 
in development are for NTDs, but only three are NCEs (for 
onchocerciasis, Chagas disease, and human African 
trypano somiasis). Two other NCEs are in development for 
other neglected diseases (Ebola and Marburg viruses). 
Vaccine (and biological-product) candidates are in less 
advanced stages of clinical development compared with 
other products, with most still in phase 1 (table 7). Of the 
34 products that are new formulations (including ﬁ xed-
dose combinations), new indications, or new associations, 
most (29 [85%]) are in phase 2 or 3 clinical trials. Of the 
16 NCEs in development, half are in phase 2 and two are in 
phase 3.
Of the 49 diseases included in this study (appendix), 
only 11 had no crucial research gaps (eg, dracunculiasis). 
For 25 diseases, research and development gaps exist and 
clinical research is ongoing to address some of these gaps 
(eg, for tuberculosis, human African trypano somiasis, 
ﬁ lariasis, snakebite). For 13 (27%) diseases, gaps exist but 
no clinical research was ongoing at the time of analysis (eg, 
Buruli ulcer, mycetoma, food-borne trematode infections).
Assessment of study sponsorship, as listed in the NIH 
and WHO clinical trials registries, for the 123 products in 
development showed the involvement of public organ-
isations in 66 products (54%), private industry in 
28 products (23%), and private not-for-proﬁ t organisations 
in 19 products (15%), with the remaining 10 products 
(8%) involving a mix of sponsors. About half of all new 
products in development sponsored by private not-for-
proﬁ t organisations are for NTDs (ten of 19), and the 
other half are for malaria, tuberculosis, and diarrhoeal 
diseases (nine of 19). All three NCEs for NTDs are being 
sponsored by private not-for-proﬁ t organisations.
Discussion
Despite substantial political attention towards the burden 
of neglected diseases, we detected no evidence of a 







Malaria 96 (31%) 23 (31%) 119 (31%)
Tuberculosis 70 (23%) 29 (39%) 99 (26%)
Diarrhoeal diseases† 34 (11%) 7 (9%) 41 (11%)
NTDs‡ 75 (24%) 12 (16%) 87 (23%)
Other§ 33 (11%) 4 (5%) 37 (10%)
Total 308 (100%) 75 (100%) 383 (100%)
Data are n (%). NIH=National Institutes of Health. NTD=neglected tropical disease 
(WHO deﬁ nition). *Two interventional studies on NTDs without phase 
information were included. †Rotavirus (15). ‡Leishmaniasis (29), dengue fever 
(27). §Japanese encephalitis (12), yellow fever (12), viral haemorrhagic fevers (9).
Table 5: Active clinical trials by neglected disease and registry type (as of 
Dec 31, 2011)
NCE NF or FDC NI NA Vaccine or 
biologics
Total
Malaria 6 (38%) 4 (50%) 5 (21%) 1 (14%) 21 (31%) 37 (30%)
Tuberculosis 5 (31%) 0 3 (13%) 3 (43%) 8 (12%) 19 (15%)
Diarrhoeal diseases 0 0 2 (8%) 0 13 (19%) 15 (12%)
NTDs* 3 (19%) 4 (50%) 10 (42%) 3 (43%) 14 (21%) 34 (28%)
Other† 2 (13%) 0 4 (17%) 0 12 (18%) 18 (15%)
Total 16 (100%) 8 (100%) 24 (100%) 7 (100%) 68 (100%) 123 (100%)
Data are n (%). NCE=new chemical entity. NF=new formulation. FDC=ﬁ xed-dose combination. NI=new indication. NA=new 
association. NTD=neglected tropical disease (WHO deﬁ nition). *Cutaneous leishmaniasis (10), dengue fever (6), visceral 
leishmaniasis (4), Chagas disease (3), schistosomiasis (3), rabies (2), one each for echinococcosis, hookworm, human African 
trypanosomiasis, lymphatic ﬁ lariasis, onchocerciasis, and cysticercosis or taeniasis. †Viral haemorrhagic fevers (6), other 
arboviruses (6), Japanese encephalitis (3), one each for yellow fever, scabies, and snakebite.
 Table 6: New products in clinical trials by neglected disease and product type (as of Dec 31, 2011)
Phase 1* Phase 2* Phase 3* Total
New chemical entity 6 (12%) 8 (17%) 2 (9%) 16 (14%)
New formulation or ﬁ xed-dose combination 2 (4%) 3 (7%) 3 (13%) 8 (7%)
New indication 3 (6%) 10 (22%) 7 (30%) 20 (17%)
New association 0 4 (9%) 2 (9%) 6 (5%)
Vaccine or biological 38 (78%) 21 (46%) 9 (39%) 68 (58%)
Total 49 (100%) 46 (100%) 23 (100%) 118 (100%)
Data are n (%).*The most advanced phase for each new product is presented. Two studies are phase 0. Study phase was 
unknown for ﬁ ve products.
Table 7: Study phase of products in development for neglected diseases, by product type (as of Dec 31, 2011)
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activity compared with previous decades. Some progress 
has been made, but these advancements have not in large 
part redressed the research and development imbalance, 
reported more than a decade ago, in truly new therapeutic 
products for neglected diseases (panel). Most new 
products are repurposed versions of existing products.
From 2000 to 2011, only 4% of all approved new 
products (a fraction of which are vaccines), and only 1% 
of all approved NCEs, were indicated for neglected 
diseases, although the global health burden of these 
diseases is estimated at 11%. Similarly, only 1% of all 
existing clinical trials in December, 2011, were for 
neglected diseases. Very few ongoing trials are assessing 
NCEs (6%), with greater emphasis on vaccines (32%) and 
repurposing of existing drugs (15%).
This study had several strengths and weaknesses. We 
applied a broad deﬁ nition of neglected diseases in an 
attempt to provide a comprehensive picture. However, 
we could not reliably estimate the burden of several of 
the diseases included, because their burden might be 
underestimated by DALYs or because data were 
unavailable.22,23 An analysis of 2010 global disease burden 
reported a similar DALY percentage for neglected 
diseases (10·5%), based on a slightly diﬀ erent list of 
diseases.24 However, due to diﬀ ering deﬁ nitions of 
neglected diseases, we excluded some diseases of 
importance to low-income countries, such as bacterial 
pneumonia and meningitis, which could arguably be 
regarded as neglected diseases. Thus, MenAfriVac 
(Serum Institute of India Ltd, Pune, India), a new vaccine 
developed for group A meningitis endemic in sub-
Saharan Africa, registered in India, and on the WHO List 
of Prequaliﬁ ed Medicinal Products, was not included.
Registration data were not openly available on the 
internet for some countries (eg, South Africa, China). 
China is not a member of the Pharmaceutical Inspection 
Co-operation Scheme. However, we think it unlikely that 
new products would be registered only in these countries 
and nowhere else. To cover all the neglected diseases in 
our analysis, we expanded the registration database 
search beyond only FDA and European Medicines 
Agency to other databases and registries of a large 
number of endemic and non-endemic countries.
Also, during the time period assessed (2000–11), the 
WHO prequaliﬁ cation process was created (in 2001) for 
drugs, especially those for HIV, tuberculosis, and malaria. 
We included new products on the WHO List of Prequaliﬁ ed 
Medicinal Products18 and WHO Essential Medicines List19 
to account for neglected-disease research and development 
eﬀ orts not captured by our search of regulatory authorities. 
Consequently, WHO prequali ﬁ cation was the basis for 
identifying all seven of the new products for tuberculosis, 
and one for malaria, in 2000–11, and the Essential 
Medicines List accounted for the new indications for 
human African trypanosomiasis, diarrhoeal disease, and 
viral haemorrhagic fevers. However, certain loose 
combinations of products that are neither registered nor 
included on the WHO Essential Medicines List (eg, the 
combination of sodium stibogluconate and paromomycin 
for the treatment of visceral leishmaniasis in Africa) were 
not counted as new products.
Use of inclusion in the WHO Essential Medicines List 
as a proxy metric for medical innovation has its limits 
because the list favours infectious diseases aﬀ ecting, and 
low-cost products for, low-income countries. Also, 
inclusion is based on voluntary application, which might 
result in the missed counting of any products for which 
the sponsor did not apply for inclusion on the list.
Findings from a 2002 analysis showed that between 
1975 and 1999 only 16 (1·1%) of 1393 new products had 
been developed for neglected diseases.6 Another analysis 
of the same period published in 2010 but using diﬀ erent 
product-approval information sources showed double 
the number of new products developed (n=32).25 For the 
period 2000–09, the same investigators reported a lower 
number of new products (26; 15 excluding HIV/AIDS, 
bacterial pneumonia, and meningitis) compared with 
our analysis. The report of 16 new products approved 
over the 25-year period of 1975–99 gives an average of 
Panel: Research in context
Systematic review
We searched PubMed for publications using the terms “neglected diseases” and “global 
burden of disease” from Jan 1, 1999, to Dec 31, 2011. We searched the publications and 
websites of WHO and organisations involved in neglected-diseases research, ﬁ nancing, and 
analysis (BIO Ventures for Global Health, Policy Cures, Global Alliance for TB Drug 
Development, Medicines for Malaria Venture [MMV], PATH, Drugs for Neglected Diseases 
initiative [DNDi]). Attrition rates applied for forecasting future product approvals came from 
two research articles30,31 and the DNDi 2011–18 Business Plan.32 We also included relevant 
publications that became available during the submission process12,29,34,35 and on the 
recommendation of a reviewer.24 A previous analysis of new therapeutic products registered 
for neglected diseases covered the period of 1975–99.6 Our objective was to assess progress 
in research and development achieved in the following decade, from 2000 to 2011. We 
identiﬁ ed another assessment of new drugs registered during 1975–99 and 2000–09, and of 
new products in clinical development in 2009,25 but this study included other diseases that 
we did not deﬁ ne as neglected (HIV/AIDS, bacterial pneumonia, meningitis) and used 
diﬀ erent sources of information. We also identiﬁ ed a study predicting future product 
approvals,29 but this analysis used more speciﬁ c criteria than our study, including predicted 
time to registration using FDA priority review vouchers and narrower disease scope.
Interpretation
The results of our analysis update the current evidence on therapeutic product approvals 
for neglected diseases through 2011, and provide future approval forecasts for the next 
decade, based on highly relevant disease scope. Our ﬁ ndings are consistent with those 
reported in similar studies,25,29 despite diﬀ erences in disease scope and methods used. 
Despite positive advances over the past decade in therapeutics for neglected diseases, a 
persistent gap remains in product development for most of the neglected diseases. 
Therapeutic advancements have for the most part been achieved through repurposed or 
reformulated versions of existing drugs. A major research and development gap remains in 
new chemical entities for neglected diseases, both in terms of recent approvals and 
ongoing clinical development. For many neglected diseases, new therapeutic products 
urgently need to be developed and delivered to improve disease control and potentially 
achieve elimination.
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0·6 product per year, whereas the 2010 report of 32 new 
products over the same time period gives an average of 
1·3 products per year. Our analysis showed that 29 new 
products, excluding vaccines and biologicals, were 
approved over the 12-year period of 2000–11, 
corresponding to an average of 2·4 products per year. 
Although direct comparison between the three studies is 
not possible because of diﬀ erences in disease and 
product deﬁ nitions and methods, their collective ﬁ ndings 
show a trend of a slight increase in products approved 
per year.
Malaria and tuberculosis accounted for 19 of the 29 new 
products approved for neglected diseases in 2000–11. 
Only ﬁ ve new products were developed for NTDs, all of 
which were for only three of the 17 NTDs as deﬁ ned by 
WHO.10 Of the 29 new products, few are truly innovative: 
most are based on the repurposing of existing treatments, 
namely reformulations, new indications, or ﬁ xed-dose 
combinations. This approach, which is faster, cheaper, 
and less risky than novel drug discovery and development, 
has resulted in some important advancements for some 
diseases, as evidenced by the relatively high level of 
inclusion of new products on the WHO Essential 
Medicines List during 2000–11 (48%).
Only four NCEs have been developed for neglected 
diseases in the past 12 years. Of these, three were for 
malaria (of which two were derivatives of artemisinin, 
which was developed in the 1970s; the third combined an 
artemisinin derivative with an existing drug), and the 
fourth NCE, nitazoxanide, was ﬁ rst developed for 
cryptosporidiosis, an HIV-related opportunistic infection, 
and was later shown to be eﬀ ective against giardiasis. 
Apart from this one NCE, no new drug class for neglected 
diseases has been approved in the past 12 years. The 
deﬁ ciency in research and development for neglected 
diseases seen in our study has also been reported in the 
area of antibiotics, where new drugs are urgently needed 
to treat drug-resistant bacterial infections.26,27
Seven of the marketing authorisations for products 
approved in 2000–11 were granted to large European 
pharmaceutical companies. This appears to represent a 
change compared to the situation over a decade ago, 
when in 2001 large pharmaceutical companies were 
reported to have spent less than 1% of their research and 
development budgets on neglected diseases over the 
previous ﬁ scal year.7 European leadership was also 
reported in 2008 and is still present in the 2012 report of 
the Access to Medicine index.28 Still, investments by the 
pharmaceutical industry have been limited to diseases 
with large volumes or a potential market, namely malaria, 
rotavirus, and Japanese encephalitis.
The development of innovative NCEs and biologicals, 
including vaccines, is a lengthy process, especially 
compared with the time taken to repurpose an existing 
drug. Recent investments and the eﬀ orts of product 
development partnerships and other partnerships have in 
large part followed the relatively easier approach of 
developing repurposed products rather than NCEs. 
However, several NCEs were in ongoing trials during the 
time of our analysis, but were not yet approved.
As of Dec 31, 2011, 123 new products were in the 
research pipeline. More than half (55%) were vaccines or 
biological products for a larger range of diseases than in 
the past. But NCEs remain poorly investigated, 
representing only 13% of the research eﬀ orts for 
neglected diseases. In terms of neglected-disease areas, 
malaria remains the primary focus of research and 
development. For NTDs, increased eﬀ orts are apparent: 
28% of new products (34 of 123) in clinical development 
for NTDs, compared with 13% of new products (ﬁ ve 
of 37) approved in 2000–11. These 34 products in 
development were intended for 11 NTDs, whereas the 
ﬁ ve new products approved in 2000–11 covered only 
three NTDs. However, three NTDs (Buruli ulcer, food-
borne trematode infections, and leprosy) and ten other 
neglected diseases remain excluded from any product 
development although new treatment or preventive 
interventions are needed.
Findings from a 2010 study showed 97 new products in 
clinical development as of July, 2009 (65 when excluding 
indications for HIV/AIDS, bacterial pneumonia, and 
meningitis), with the most being vaccines (46 of 65).25 
This ﬁ nding is consistent with our ﬁ ndings, which 
covered a more recent period (until December, 2011). 
Another study looking at products developed for 
neglected diseases that could potentially be granted an 
FDA priority review voucher detected 62 new products in 
clinical development in July, 2011 (17 drugs and 
45 vaccines), for 16 neglected diseases.29 Despite 
diﬀ erences in methodology, these ﬁ ndings also showed a 
high proportion of vaccine candidates in development. 
Unsurprisingly, clinical trials investigating new 
indications of existing drugs were at a more advanced 
stage than vaccine trials, which are mostly in phase 1 or 
NCE trials, which are mostly phases 1–2.
The predicted number of new products (excluding 
vaccines and biologicals) for neglected diseases to be 
approved in the coming years can be estimated by 
extrapolating the number of products in phase 1–3 
clinical development and applying an attrition rate for 
infectious diseases.30–32 Success rates applied were 70% 
for NCEs in phase 1, 50% for those in phase 2, and 65% 
for those in phase 3, and 80% for all phases for new 
indications, associations, and formulations, except 70% 
for phase 1 and 85% for phase 3 of new formulations. 
Predicted registration success rates were 95% for NCEs 
and 100% for other products. We forecast that the current 
pipeline has the potential to deliver about 28 new 
registered products over the next 6 years, but only ﬁ ve 
NCEs. This forecasted estimate corresponds to an 
average of 4·7 new products per year through 2018, 
which represents a considerable acceleration compared 
with the ﬁ nding of an average of 2·4 new products per 
year developed in 2000–11.
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For vaccines and biologicals, 15 new products could be 
expected in the next 10 years applying a conservative 22% 
success rate,33 again suggesting an accelerating trend in 
research and development. Vaccine development 
generally has higher attrition rates and longer timelines 
than does drug development, and early clinical trials for 
vaccines cannot be compared directly with early clinical 
trials for drugs when predicting approvals. Another 
assessment of NTD drug and vaccine approvals predicted 
lower numbers than our forecast of new products in the 
next 5 years, though this prediction is based on more 
speciﬁ c criteria, including time to registration using a 
speciﬁ c FDA-approval pathway for neglected diseases, 
and narrower disease scope.29
Ongoing clinical research will probably bring new 
treatment options for malaria and tuberculosis, with 
several NCEs in the pipeline, but is not likely to produce 
a substantial number of NCEs for other neglected 
diseases. Even if vaccine development accelerates and 
oﬀ ers potential solutions in the future, the overall health 
burden of neglected diseases will not be resolved. 
Vaccines will probably not be developed for every 
neglected disease, and in the short term, patients with 
infections and at risk of death or serious disability will 
require immediate treatment. The spread of resistance to 
infectious and parasitic organisms, notably to malaria, 
tuberculosis, and diarrhoeal infections, and the toxicity 
and burdensome administration of some treatments, 
still justify the development of new products for most 
neglected diseases.
The anticipated near-doubling of new products in the 
coming years compared with previous years is the result 
of substantial changes to the research and development 
landscape over the past 15 years. New consortia, 
partnerships, and business models for drug discovery 
have emerged, including product development 
partnerships, which have attempted to ﬁ ll research and 
development gaps and catalyse new eﬀ orts for several 
neglected diseases. With the support of new private and 
public funding, including important contributions by the 
Bill & Melinda Gates Foundation since 2000, there has 
been an increase of resources allocated to innovation for 
neglected diseases, reaching US$3 billion in 2011.34 
Nevertheless, in 2010 only 1% of research and 
development investment for global health was allocated 
to neglected diseases.35
Although the public sector provides two-thirds of all 
research and development funding for neglected 
diseases, at nearly $2 billion per year, government 
funding is shifting away from product development and 
towards traditional basic research.34 Additionally, funding 
by industry and philanthropy, the sectors that customarily 
fund product development, is dropping or refocusing on 
only a few products and diseases, namely dengue fever, 
tuberculosis, and bacterial pneumonia and meningitis.34
Our analysis shows that public organisations have a 
leading role as the main sponsor for more than half (54%) 
of all products in clinical development for neglected 
diseases. For NTD drug development, public institutions 
and private not-for-proﬁ t organisations play an important 
part as product clinical-trial sponsors, and for vaccine 
development, the pharmaceutical industry is the leading 
sponsor. Private industry sponsors nearly a quarter (23%) 
of new product trials for neglected diseases, compared 
with a near standstill in product development a decade 
ago.2,31 However, we were not able to assess all partnerships 
and collaborations involved in the development of new 
products for neglected diseases.
Our ﬁ ndings show a persistent deﬁ ciency in product 
development for neglected diseases, although in the past 
12 years positive advances have been seen for neglected-
disease treatments, based mainly on the number of newly 
approved drug reformulations, repurposed products, and 
vaccines, as well as the number of ongoing clinical trials, 
especially for vaccines. Nevertheless, a major research 
and development gap remains in NCEs for neglected 
diseases, both in terms of new approvals and ongoing 
clinical development as shown by only 1% of existing 
clinical trials focused on this area. Malaria, tuberculosis, 
and diarrhoeal diseases remain the main focus of product-
development research, with little focus on other neglected 
diseases. Providing the required treatments to control 
and then eliminate neglected diseases is a crucial concern 
and will require investment eﬀ orts into research and 
development for neglected diseases on all fronts.
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